Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2,... | March 23, 2023
Source: marketscreener.com